Following the recent FDA approval of repotrectinib, the NCCN guidelines have been updated to include crizotinib, entrectinib, or repotrectinib as preferred first-line therapy for metastatic ROS1+ NSCLC (Figure 2).17,43 Prospective trial data comparing each of these first-line options are not yet available; however, ongoing phase III trials are comparing crizotinib versus entrectinib (NCT04603807) and crizotinib versus repotrectinib (NCT06140836; TRIDENT-3).50,51. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.